Currently, chimeric antigen receptor T-cell immunotherapy (CART), an emerging hotspot therapy for DLBCL, in vivo CAR-T cell expansion is dominated by CD8+ T cells and is most significantly associated with durable responses in patients with relapsed/refractory DLBCL (r/r DLBCL) [33–35]. This evidence concerns the gene CD8A and diffuse large B-cell lymphoma.